SQY Therapeutics, UFR des Sciences de la Santé , Montigny-le-Bretonneux, France.
Université de Versailles Saint-Quentin en Yvelines, U1179 INSERM/UVSQ, UFR des Sciences de la Santé , Montigny-le-Bretonneux, France.
Mol Ther Methods Clin Dev. 2016 May 11;3:16035. doi: 10.1038/mtm.2016.35. eCollection 2016.
Recombinant adeno-associated viruses (rAAV) are largely used for gene transfer in research, preclinical developments, and clinical trials. Their broad in vivo biodistribution and long-term efficacy in postmitotic tissues make them good candidates for numerous gene transfer applications. Upstream processes able to produce large amounts of rAAV were developed, particularly those using baculovirus expression vector system. In parallel, downstream processes present a large panel of purification methods, often including multiple and time consuming steps. Here, we show that simple tangential flow filtration, coupled with an optimized iodixanol-based isopycnic density gradient, is sufficient to purify several liters of crude lysate produced by baculovirus expression vector system in only one working day, leading to high titers and good purity of rAAV products. Moreover, we show that the viral vectors retain their in vitro and in vivo functionalities. Our results demonstrate that simple, rapid, and relatively low-cost methods can easily be implemented for obtaining a high-quality grade of gene therapy products based on rAAV technology.
重组腺相关病毒(rAAV)在研究、临床前开发和临床试验中被广泛用于基因转移。它们在体内的广泛分布和在有丝分裂后组织中的长期疗效使它们成为许多基因转移应用的良好候选物。已经开发出能够大量生产 rAAV 的上游工艺,特别是那些使用杆状病毒表达载体系统的工艺。同时,下游工艺提供了大量的纯化方法,通常包括多个耗时的步骤。在这里,我们展示了简单的切向流过滤,结合优化的基于碘克沙醇的等密度梯度,足以在仅一天的工作时间内纯化几升由杆状病毒表达载体系统产生的粗裂解物,从而获得高滴度和良好纯度的 rAAV 产物。此外,我们还证明了病毒载体保留了其体外和体内功能。我们的结果表明,简单、快速且相对低成本的方法可以轻松实施,从而获得基于 rAAV 技术的高质量基因治疗产品。